- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05449080
Disorders of Sex Development (DSD) 46.XY in Three Siblings
July 3, 2022 updated by: Universitas Padjadjaran
Disorders of Sex Development (DSD) 46.XY Due to Type 2 5-Α Reductase Deficiency in Three Siblings: Case Report From a Low-Resource Setting
This is a case series of three siblings with DSD 46,XY with relevant discussion
Study Overview
Detailed Description
This is a case series of three sisters with DSD 46 X,Y.
Three sisters, aged nineteen, seventeen, and fifteen years old came with an identical complaint of late menarche.
Physical examinations, lab results and karyotypes were performed.
Study Type
Observational
Enrollment (Actual)
3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Bandung, Indonesia, 40161
- Department of Obstetrics and Gynecology, Universitas Padjadjaran
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Sampling Method
Non-Probability Sample
Study Population
The patients were 3 female siblings with identical complaints of no menarche of varying ages.
Patients were subjected to physical examination, lab tests and karyotype to determine their genotypes.
Description
Inclusion Criteria:
- 3 female siblings with identical complaints of no menarche
Exclusion Criteria:
- patients outside this family.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Cases
subjects with type 2 5-alpha reductase deficiency
|
Patients were subjected to karyotype to determine their genotype
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Karyotype
Time Frame: 1 month after testing
|
Patient's karyotype
|
1 month after testing
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Marzuki NS, Idris FP, Kartapradja HD, Harahap AR, Batubara JRL. Characterising SRD5A2 Gene Variants in 37 Indonesian Patients with 5-Alpha-Reductase Type 2 Deficiency. Int J Endocrinol. 2019 Dec 1;2019:7676341. doi: 10.1155/2019/7676341. eCollection 2019.
- Walter KN, Kienzle FB, Frankenschmidt A, Hiort O, Wudy SA, van der Werf-Grohmann N, Superti-Furga A, Schwab KO. Difficulties in diagnosis and treatment of 5alpha-reductase type 2 deficiency in a newborn with 46,XY DSD. Horm Res Paediatr. 2010;74(1):67-71. doi: 10.1159/000313372. Epub 2010 Apr 16.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
October 1, 2021
Primary Completion (ACTUAL)
December 1, 2021
Study Completion (ACTUAL)
December 31, 2021
Study Registration Dates
First Submitted
June 26, 2022
First Submitted That Met QC Criteria
July 3, 2022
First Posted (ACTUAL)
July 8, 2022
Study Record Updates
Last Update Posted (ACTUAL)
July 8, 2022
Last Update Submitted That Met QC Criteria
July 3, 2022
Last Verified
July 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- OBGY-202206.03
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
IPD Plan Description
Anonymous data on female subjects may be shared with reasonable written request to the authors.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Genotype
-
Bristol-Myers SquibbCompletedHCV (Genotype 1)United States, Puerto Rico
-
Sequenom, Inc.NAFTNetCompleted
-
Sequenom, Inc.Sequenom Center for Molecular MedicineCompleted
-
California Pacific Medical Center Research InstituteChildren's Mercy Hospital Kansas CityWithdrawnMethamphetamine Metabolism, CYP2D6 GenotypeUnited States
-
The Eye Hospital of Wenzhou Medical UniversityRecruiting
-
National Research Council, SpainIMDEA Food; CEIP (primary school) Jara Carrillo (Alcantarilla, Murcia, Spain); IES (secondary school) Alcántara (Alcantarilla, Murcia, Spain)CompletedGenotype, Metabotype and Dietary HabitsSpain
-
Inje UniversityCompletedHealthy Subjects | Genotype Guided(HNF4a)
-
Chinese Academy of SciencesLanZhou UniversityCompletedPharmacokinetic | GenotypeChina
-
National Taiwan University HospitalNot yet recruitingThe Influence of the UGT1A1 Genotype
-
Bispebjerg HospitalUniversity of Copenhagen; Duke University; The Ministry of Science, Technology... and other collaboratorsCompletedCarboxylesterase 1 (CES1) Genotype | CES1 ActivityDenmark
Clinical Trials on Karyotype
-
Instituto Nacional de Cancerologia de MexicoCompletedPromyelocytic Leukemia, AcuteMexico